Browse the evidence

Co-stimulation of GLP-1 with other receptors like GIP and glucagon may provide additional therapeutic benefits.

Practitioners should consider combination therapies involving GLP-1 for enhanced weight loss effects.

Metformin was widely found to be weight-neutral with minimal effects on muscle mass.

Practitioners can consider Metformin as a weight-neutral option with minimal impact on muscle mass.

GLP-1 RA initiation was associated with a reduced incidence of all-cause mortality post RYGB (1.2% vs. 3.9%) with a hazard ratio of 0.497.

Practitioners may consider GLP-1 RAs to potentially improve survival rates in patients post RYGB.

The blood pressure-lowering effects of GLP-1 RAs are often independent of weight loss or glucose control.

GLP-1 RAs may be beneficial for hypertension management even in patients not focused on weight loss or glucose control.

Emerging translational applications include diagnostic and prognostic adipokine signatures and therapeutic impacts of GLP-1 receptor agonists.

These applications could enhance clinical practice in managing HFpEF.

Evidence suggests a reduced incidence of several gastrointestinal cancers with GLP-1 receptor agonist use.

GLP-1 receptor agonists may be considered for patients at risk of gastrointestinal cancers.

The development of oral formulations such as oral Semaglutide is expected to provide convenience for patients and enhance their willingness to receive treatment.

Practitioners should consider the potential of oral Semaglutide to improve patient adherence to obesity treatment.

GLP-1 receptor agonists (GLP-1RAs) have adverse events associated with their increased use.

Practitioners should be aware of the potential adverse events when prescribing GLP-1RAs.

GLP-1RAs users demonstrated significantly reduced risks of poor functional outcomes (odds ratio 0.37, 95% CI 0.21-0.66).

Using GLP-1 receptor agonists may enhance functional recovery in patients post-treatment.

GLP-1RAs users had significantly reduced risks of new subarachnoid hemorrhage (odds ratio 0.39, 95% CI 0.27-0.56).

GLP-1 receptor agonists may lower the risk of subarachnoid hemorrhage in treated patients.

Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Practitioners should adopt a long-term management strategy for obesity treatment.

NN501 causes weight loss without causing obvious aversive responses.

NN501 may provide a weight loss option without the side effects commonly associated with other treatments.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of corticosteroid use in patients with inflammatory bowel disease (IBD) compared to non-GLP-1 users.

Clinicians can consider GLP-1RAs for weight management in IBD patients without concern for increased corticosteroid use.

Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689) and 24 months postoperatively (5% vs. 7%; OR=0.692).

GLP-1RAs may help reduce the need for reoperation in ACDF patients.

GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF.

GLP-1RAs may significantly improve postoperative outcomes in ACDF patients.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events and non-fatal stroke in patients with type 2 diabetes mellitus.

Practitioners should consider GLP-1RAs as a therapeutic option for reducing cardiovascular risks in patients with type 2 diabetes.

GLP-1RAs are being studied in clinical settings not previously examined in original trials.

Practitioners should stay informed about the evolving applications of GLP-1RAs in clinical practice.

Naltrexone/bupropion may benefit sexual desire through mood improvement.

Practitioners might consider Naltrexone/bupropion for patients seeking improvements in sexual desire linked to mood.

DPP-4 inhibitors offer stroke prevention and cognitive advantages, particularly in patients with renal impairment.

DPP-4 inhibitors may be considered for patients at risk of stroke and cognitive decline.

GLP-1RA therapy was associated with a lower risk of all-cause mortality in nondiabetic patients with PAD (HR: 0.40; 95% CI: 0.35–0.46; p < 0.001).

GLP-1RAs may help reduce overall mortality in patients with PAD who do not have diabetes.

GLP-1RA therapy was associated with a lower risk of major adverse limb events (MALE) in nondiabetic patients with PAD (HR: 0.22; 95% CI: 0.17–0.28; p < 0.001).

GLP-1RAs may reduce the risk of serious limb complications in patients with PAD who do not have diabetes.

Tirzepatide has a favorable safety profile but requires further investigation.

Practitioners should consider tirzepatide as a treatment option while monitoring for adverse reactions.

Ambulatory blood pressure monitoring strengthens the association between blood pressure control and cardiovascular outcomes.

Utilizing ambulatory BP monitoring may improve cardiovascular risk assessment in patients treated with GLP-1RA.

Amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators.

Amylin receptor activators may be a safer alternative to GLP-1 receptor activators for patients.